Wikisage, the free encyclopedia of the second generation, is digital heritage
Belzutifan: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease. | Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von [[Hippel-Lindau disease]]. | ||
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). | Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). | ||
Revision as of 23:54, 13 August 2021
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]
ATC
none
|
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]
External links
Ben-Skowronek I, Kozaczuk S 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323
| References: |
|